Pharmaceutical firm Suven Life Sciences has been granted a patent each by Eurasia and Israel for drug used in the treatment of neuro-degenerative diseases.
Neuro-degenerative ailments include Alzheimer's disease, Schizophrenia and Parkinson's disease.
In a BSE filing, the company said it has received "grant of one product patent from Eurasia and one product patent from Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases."
These patents are valid until 2029 and 2030 respectively, it added.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for major depressive disorder (MDD) with high unmet medical need with huge market potential globally," Suven Life Sciences CEO Venkat Jasti said.
With these new patents, Suven has a total of 14 granted patents from Eurasia and three from Israel. "These patents are exclusive intellectual property of Suven products out of these inventions may be out-licensed at various phases of clinical development like at Phase-1 and Phase-2," Suven Life Sciences said.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
